Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 14699048)

1.

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602. Epub 2003 Dec 29.

2.

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG.

J Clin Invest. 2004 Feb;113(4):528-38.

3.

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.

4.

Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia.

Chan IT, Gilliland DG.

Cell Cycle. 2004 May;3(5):536-7. Epub 2004 May 5.

5.

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.

PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.

6.

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS.

Blood. 2007 May 1;109(9):3945-52. Epub 2006 Dec 27.

7.

Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.

Wang J, Liu Y, Tan LX, Lo JC, Du J, Ryu MJ, Ranheim EA, Zhang J.

Cell Cycle. 2011 Sep 1;10(17):2836-9. Epub 2011 Sep 1.

8.

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM.

Blood. 2004 Jun 1;103(11):4243-50. Epub 2004 Feb 24.

9.

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ, Meline B, Du J, Young KH, Ranheim E, Chang Q, Zhang J.

Blood. 2011 Jul 14;118(2):368-79. doi: 10.1182/blood-2010-12-326058. Epub 2011 May 17.

10.

Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J.

J Clin Invest. 2014 Jun;124(6):2762-73. doi: 10.1172/JCI74182. Epub 2014 May 8.

11.

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K.

Blood. 2006 Sep 15;108(6):2041-4. Epub 2006 May 23.

12.

Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.

MacKenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G.

Blood. 1999 Mar 15;93(6):2043-56.

13.

Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease.

Wahlstrom AM, Cutts BA, Karlsson C, Andersson KM, Liu M, Sjogren AK, Swolin B, Young SG, Bergo MO.

Blood. 2007 Jan 15;109(2):763-8. Epub 2006 Sep 14.

14.

Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.

Cutts BA, Sjogren AK, Andersson KM, Wahlstrom AM, Karlsson C, Swolin B, Bergo MO.

Blood. 2009 Oct 22;114(17):3629-32. doi: 10.1182/blood-2009-02-205146. Epub 2009 Aug 26.

15.
17.

Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.

Chung E, Hsu CL, Kondo M.

PLoS One. 2011;6(12):e28350. doi: 10.1371/journal.pone.0028350. Epub 2011 Dec 2.

18.

PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.

Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K.

Sci Signal. 2013 Dec 3;6(304):ra105. doi: 10.1126/scisignal.2004125.

19.

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K.

Cancer Discov. 2013 Sep;3(9):993-1001. doi: 10.1158/2159-8290.CD-13-0096. Epub 2013 Jun 3.

20.

Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.

Munugalavadla V, Sims EC, Chan RJ, Lenz SD, Kapur R.

Exp Hematol. 2008 Mar;36(3):301-8. doi: 10.1016/j.exphem.2007.11.008. Epub 2008 Jan 7.

PMID:
18179858
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk